TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: static balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-stimulated glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-stimulated GS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean improvement in NFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in parent mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Line crossings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleepiness scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Disease-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe side effects
Endpoint domain: Adverse events/effects
Primary endpoint: sudden death rate
Endpoint domain: Mortality/survival
Primary endpoint: utility scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: healthcare service costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median proximal penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median proximal penetration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median total penetration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sTnI levels postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ongoing pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: mean number of metaphase II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Treatment effects score points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medial femur bone area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pgp serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: purchase intention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Relapse of overt hyperthyroidism
Endpoint domain: Mortality/survival
Primary endpoint: Cout difference between methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVI estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beliefs about personal control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily impairment due to pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall status improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of hypotony
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of anterior chamber shallowing
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of choroidal detachment
Endpoint domain: Adverse events/effects
Primary endpoint: time to resolution of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of RAW outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial response to treatment (ultrasound measurements)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary hemodynamic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: A-aDO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of cyanopsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients taking vitamins or supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: graft loss due to BOS
Endpoint domain: Mortality/survival
Primary endpoint: incidence of acute rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glasgow Coma Score of eight or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Airway problems requiring an adjunct
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of cervical intraepithelial neoplasia (CIN) type 2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of cervical intraepithelial neoplasia (CIN) type 3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase delay index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance and functional mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of depressive symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1RM leg press
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean group number of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Back pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (Physical Component Summary score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (Mental Component Summary score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall rate of survival at two years
Endpoint domain: Mortality/survival
Primary endpoint: rate of local recurrence at two years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: response rate for atenolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment related dropout rate
Endpoint domain: Adverse events/effects
Primary endpoint: Homeostatic sensations (satiety, fullness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hedonic responses (digestive well-being and mood)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in hypoglycemic fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in regimen burden
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction of Tinnitus Questionnaire (TQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative anastomotic stricture
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of postoperative GI bleeding from the gastrojejunostomy
Endpoint domain: Adverse events/effects
Primary endpoint: global improvement scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adequate relief of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contraceptive uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of long-acting contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat abortions
Endpoint domain: Adverse events/effects
Primary endpoint: Ps-a CO2 gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean standing height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean spine height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean leg length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean upper limb length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean utilities of health states
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: disutilities associated with oral medications
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in tumor glandular cellularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of shivering
Endpoint domain: Adverse events/effects
Primary endpoint: fast walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBS (Berg Balance Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DGI (Dynamic Gait Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC (Activities-specific Balance Confidence Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FM (Fugl-Meyer Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfortable volume perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time to recovery of the T(4)/T(1) ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fexofenadine area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma drug concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intubation (T2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of systemic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nostril width ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alveolar ulceration frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in total Genant-modified Sharp scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with no progression of structural damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Fib, DD, ET, CD62p, NO, and SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total effective rate in relieving TCM syndromes and angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of electrocardiogram improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exclusive breastfeeding rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Twenty-four-hour postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-dimer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Banked blood received postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual clarity and ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical and endoscopic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function improvement (MMSE values)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 30-day adverse outcome (death and/or ICU admission)
Endpoint domain: Adverse events/effects
Primary endpoint: 18-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: IL-6-to-IL-10 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: %predPEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Asthma Control Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma Quality of Life Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients with > or = 50% biomarker decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels (TNF-alpha, IL-6, IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of celiac disease (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of false lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in true lumen size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ventilator-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence of quinapril preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative suture line bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight regain after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular ejection fraction (RVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CV death or HF rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Symptoms and signs of dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonfatal vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: major vascular procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: all vascular events and procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of D‐dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CKMB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HAV antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T-wave inversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indwelling time of bladder and drain catheters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 24-hour urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sexual side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Maxillary development assessed by Goslon Yardstick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to incipient and overt diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Incidence of strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: femoral blood flow during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of emergency department recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Refusal rates for recruitment strategies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: maternal satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibody response to AMA1-C1 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lipid peroxidation measured as MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum copper level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum selenium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe complications within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: reoperation rates for small bowel obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Physical Activity (PA) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of smoking cessation counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of referral to cessation program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of treatment attendance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean admittance-delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean interval from membrane rupture to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxytocin necessity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Drug Liking VAS E max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini Mental State Examination score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EuroQol-5D index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tolerability of hLF1-11
Endpoint domain: Adverse events/effects
Primary endpoint: Fully breast fed on discharge home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of diagnostic tests performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of stay in observation unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daclatasvir AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daclatasvir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever control (AUC for ΔT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Improvement (RI) compared to DE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasomotorial symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supplemental analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical aspiration during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: 6-minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IGF‐I standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative dose and cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Paraprosthetic regurgitation
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased incidence of sudden death
Endpoint domain: Mortality/survival